12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

NCT02586909 · clinicaltrials.gov ↗
PHASE3
Phase
TERMINATED
Status
1099
Enrollment
INDUSTRY
Sponsor class

Stopped Intepirdine did't meet primary efficacy endpoints in lead-in study RVT-101-3001

Conditions

Interventions

Sponsor

Axovant Sciences Ltd.